$0.3900
At close: Nov 18, 3:56 PM EDT
Comments
Loading...
Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) Stock, Earnings Estimates, EPS, And Revenue
Seelos Therapeutics Inc COM PAR NEW $0.001 reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Aug 14
EPS
$0.120
Quarterly Revenue
$376.00 K
Annual Revenue
–
Analyze the earnings history of Seelos Therapeutics Inc COM PAR NEW $0.001 using advanced sorting and filters.
Data brought to you by Benzinga APIs
Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Mar 2024 | 2024-05-14 | $-1.60 | $-1.48 | -8.11 % |
| Dec 2023 | 2024-03-06 | $-6.32 | $-6.40 | 1.25 % |
| Sep 2023 | 2023-11-14 | $-28.80 | $-14.40 | -100.0 % |
| Jun 2023 | 2023-08-14 | $-52.80 | $-21.60 | -144.4 % |
Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Jun 2024 | 2024-08-14 | $376.00K | $300.00K | 25.3 % |
| Mar 2024 | 2024-05-14 | $579.00K | $300.00K | 93.0 % |
| Sep 2023 | 2023-11-14 | $406.00K | $100.00K | 306.0 % |
FAQ
When is Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL) reporting earnings?
Seelos Therapeutics Inc COM PAR NEW $0.001 (SEEL) is scheduled to report earnings on March 5, 2025. The last reported earnings were for reported on August 14, 2024 for Q2.
What were the latest earnings per share (EPS) for Seelos Therapeutics Inc COM PAR NEW $0.001 (OTC:SEEL)?
The Actual EPS was $0.12, which beat the estimate of $0.00.
What were Seelos Therapeutics Inc COM PAR NEW $0.001’s (OTC:SEEL) revenues?
The Actual Revenue was $376K, which beat the estimate of $300K.
Browse earnings estimates, EPS, and revenue on all stocks.